Mobile

Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders

Update Il y a 4 ans
Reference: NCT02502903

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Prospective, double-blind, randomized, placebo-controlled First-In-Human study with three sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in NHVs, Part C, a multiple dose (MD) study in patients with a complement-mediated disorder.

Inclusion criteria

  • Bullous Pemphigoid (BP),Cold agglutinin disease,Warm Autoimmune Hemolytic Anemia,End-Stage Renal Disease (ESRD)

Links